

Supplementary information for

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the United States: a retrospective real-world chart review study and meta-analysis.

Authors and affiliations

Dr. Anders L. Carlson,¹ Dr. Timothy Dilon Daniel,² Dr. Andrea DeSantis,³ Prof. Serge Jabbour,⁴ Dr. Esra Karslioglu French,⁵ Davida Kruger NP,⁶ Dr. Eden Miller,⁷ Dr. Kerem Ozer,⁸ Dr. Tom Elliott⁹

1. International Diabetes Center IDC, HealthPartners Institute, Minneapolis, MN, USA;
2. Diabetes Wellness Clinic, Pearland, TX, USA;
3. The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, NC, USA;
4. Thomas Jefferson University, Diabetes Research Center, Philadelphia, PA, USA;
5. University of Pittsburgh Medical Center, Pittsburgh, PA, USA;
6. Henry Ford Health System, Division of Endocrinology, Diabetes, Detroit, MI, USA;
7. Diabetes and Obesity Care LLC, Oregon, OR, USA;
8. Texas Diabetes & Endocrinology, Round Rock, TX, USA,
9. BC Diabetes, Vancouver, BC, Canada.

Table S1: Changes in HbA1c by age, sex at birth, duration of insulin use and BMI for the USA cohort and the combined group

Measure		N	Baseline Mean \pm SD	Final Phase (days 90-194) Mean \pm SD	Change Mean \pm SD	95% CI for Change	P-Value
USA							
HbA1c (%)		100	9.4 \pm 1.0	8.0 \pm 1.2	-1.4 \pm 1.3	(-1.6 to -1.1)	<0.0001
HbA1c (%) by age group (years)	<65	85	9.5 \pm 1.1	8.0 \pm 1.2	-1.5 \pm 1.3	(-1.8, -1.2)	<.0001
	\geq 65	15	9.0 \pm 0.6	8.1 \pm 1.0	-0.9 \pm 0.8	(-1.3, -0.4)	0.0010
HbA1c (%) by baseline measurement	<9.0	37	8.4 \pm 0.3	7.7 \pm 0.6	-0.8 \pm 0.7	(-1.0, -0.5)	<.0001
	\geq 9.0	63	10.0 \pm 0.9	8.2 \pm 1.4	-1.7 \pm 1.4	(-2.1, -1.4)	<.0001
HbA1c (%) by blood glucose test frequency per day	\leq 2	42	9.3 \pm 0.9	7.9 \pm 0.9	-1.4 \pm 1.0	(-1.7, -1.0)	<.0001
	>2	13	9.5 \pm 1.2	8.6 \pm 2.0	-0.9 \pm 1.5	(-1.8, 0.0)	0.0579
HbA1c (%) by BMI (kg/m ²)	<30.0	16	9.3 \pm 0.8	7.7 \pm 0.7	-1.6 \pm 1.1	(-2.1, -1.0)	<.0001
	\geq 30.0	81	9.4 \pm 1.0	8.1 \pm 1.3	-1.3 \pm 1.3	(-1.6, -1.0)	<.0001
HbA1c (%) by duration of insulin use (years)	<4	50	9.4 \pm 1.0	8.2 \pm 1.4	-1.2 \pm 1.3	(-1.6, -0.9)	<.0001
	\geq 4	50	9.4 \pm 1.0	7.9 \pm 0.8	-1.5 \pm 1.3	(-1.9, -1.2)	<.0001
HbA1c (%) by sex at birth	Female	48	9.5 \pm 1.1	8.0 \pm 1.0	-1.5 \pm 1.2	(-1.8, -1.1)	<.0001
	Male	52	9.3 \pm 0.9	8.0 \pm 1.3	-1.3 \pm 1.3	(-1.7, -0.9)	<.0001
Combined cohort							
HbA1c (%)		191	9.2 \pm 1.0	8.1 \pm 1.1	-1.1 \pm 0.14	(-1.4 to -0.8)	<0.0001
HbA1c (%) by age group (years)	<65	127	9.3 \pm 1.0	8.0 \pm 1.1	-1.3 \pm 1.3	(-1.5, -1.1)	<.0001
	\geq 65	64	8.9 \pm 0.8	8.1 \pm 0.9	-0.7 \pm 1.1	(-1.0, -0.5)	<.0001
HbA1c (%) by baseline measurement	<9.0	97	8.4 \pm 0.3	7.9 \pm 0.7	-0.6 \pm 0.74	(-0.7, -0.4)	<.0001
	\geq 9.0	94	10.0 \pm 0.8	8.3 \pm 1.3	-1.7 \pm 1.38	(-2.0, -1.4)	<.0001
HbA1c (%) by blood glucose test frequency per day	\leq 2	89	9.2 \pm 0.9	7.9 \pm 0.9	-1.2 \pm 1.1	(-1.5, -1.0)	<.0001
	>2	18	9.4 \pm 1.2	8.5 \pm 1.7	-1.0 \pm 1.5	(-1.7, -0.3)	0.0104
HbA1c (%) by BMI (kg/m ²)	<30.0	67	9.0 \pm 0.9	8.1 \pm 0.9	-0.9 \pm 1.1	(-1.2, -0.6)	<.0001
	\geq 30.0	117	9.3 \pm 1.0	8.0 \pm 1.2	-1.2 \pm 1.3	(-1.5, -1.0)	<.0001
HbA1c (%) by duration of insulin use (years)	<4	97	9.2 \pm 0.9	8.1 \pm 1.3	-1.1 \pm 1.3	(-1.3, -0.8)	<.0001
	\geq 4	94	9.2 \pm 1.0	8.0 \pm 0.8	-1.2 \pm 1.2	(-1.4, -0.9)	<.0001
HbA1c (%) by sex at birth	Female	76	9.2 \pm 1.0	8.1 \pm 1.0	-1.1 \pm 1.3	(-1.4, -0.8)	<.0001
	Male	115	9.1 \pm 1.0	8.0 \pm 1.1	-1.1 \pm 1.2	(-1.3, -0.9)	<.0001

Table S2: Demographics and Baseline Characteristics (N=91) for the Canada cohort

	n	Mean ± SD
Age (years)	91	64.3 ± 10.9
BMI (kg/m ²)	87	30.5 ± 7.6
Duration of insulin use (years)	91	4.1 ± 3.0
Baseline HbA1c (%)	91	8.9 ± 0.9
Baseline HbA1c (mmol/mol)	91	74.1 ± 9.7
n (%)	(n=91)	
Male	63 (69.2)	
Female	28 (30.8)	
Additional antihyperglycemic medications at time of starting flash sensor glucose monitoring	Any oral antihyperglycemic medication	87 (95.6)
	Metformin	69 (75.8)
	SGLT-inhibitors	57 (62.6)
	DPP4 Inhibitors	35 (38.5)
	Sulphonylureas	30 (33.0)
	TZD's	1 (1.1)
	GLP1- agonists	44 (48.4)